Therapeuticsmd Inc (TXMD) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Industry, else..
 
Therapeuticsmd Inc   (NASDAQ: TXMD)
 

Therapeuticsmd Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TXMD Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) -8.72 % 12.22 % 8.91 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 20.03 % -2.93 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 45.59 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) -2.48 % 2.69 % 2.03 % 2.61 %
Revenue 5 Year Average Growth -45.84 % 7.41 % 8.65 % 10.59 %


TXMD's Growth Comparisons in II. Quarter 2026




Although the Major Pharmaceutical Preparations industry saw advancing Revenue by 12.22%, Therapeuticsmd Inc announced -8.72% year on year sales decline in the second quarter 2026, to $ 1 millions, and underperformed the 8.91% Revenue growth in the Healthcare sector. Comparing the second quarter, sales Therapeuticsmd Inc was trailing overall market not just Major Pharmaceutical Preparations industry.

Company's sequential top-line increase was 20.03% from the first quarter. Average annual sales rise for Therapeuticsmd Inc is -45.84%, while S & P 500's average yearly sales growth is 10.59% over the five years, including only Businesses with the second quarter 2026 Results.

TXMD Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
All Other Segments
-
-
Total
-
20.03 %


Growth Rates of TXMD's Income in the second quarter 2026


TXMD Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - -8.88 % 4.62 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) - -4.52 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) - 30.63 % 30.73 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) - -2.27 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) -69.91 % -34.9 % -25.98 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) 59.22 % -2.61 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) - 6.3 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) - -10.02 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -0.55 % 0.17 % -28.52 %

TXMD Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) -71.87 % -35.09 % -26.26 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) 63.16 % 2.87 % -0.77 % 27.07 %
Y / Y Net Income Change (Q2 TTM) - 5.21 % 15.51 % 57.33 %
Sequential Net Income Change (Q2 TTM) - -10.17 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth - 14.55 % 9.21 % 22.96 %

TXMD's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) -80 % -40.27 % -25.98 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) 0 % -7.72 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) - - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - -10.79 % 0.17 % -28.52 %



TXMD EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) -80 % -40.45 % -26.26 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) 0 % -2.53 % -0.77 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) - - - 4.93 %
EPS Net 5 Year Avg. Change - 14.55 % 9.21 % 22.96 %



As Therapeuticsmd Inc 's income per share faded by -80% year on year in the second quarter, Major Pharmaceutical Preparations industry fell only by -40.45%, Therapeuticsmd Inc 's second quarter performance was trailing Major Pharmaceutical Preparations, and underperformed the -26.26% EPS slide in the Healthcare sector. Weak second quarter income per share, in Major Pharmaceutical Preparations industry and within the Healthcare sector, were reflected in Therapeuticsmd Inc results which underperformed overall market.

Sequentially company's EPS were unchanged from the first quarter results. . Looking into annual growth, income per share grew by -45.84% on average in the last five years, while the S & P 500's including only the businesses with the second quarter 2026 financial results, average yearly income per share growth is 22.96%.

TXMD Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) 104.46 % 25.53 % 48.49 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) -17.48 % -42.37 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) - 11.91 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) 14.75 % 3.24 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) 2138.1 % - - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) - 11.25 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) - -25.6 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) - 16.65 % 7.87 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) - 2.92 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change - 8.94 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.